Alector (ALEC)
(Delayed Data from NSDQ)
$5.28 USD
+0.06 (1.15%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $5.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.28 USD
+0.06 (1.15%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $5.28 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Zacks News
Alector (ALEC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 18.37% and 5.94%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Akoya Biosciences (AKYA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Akoya (AKYA) delivered earnings and revenue surprises of 0% and 1.89%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Moves 9.3% Higher: Will This Strength Last?
by Zacks Equity Research
Prothena (PRTA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 20.83% and 8.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
by Zacks Equity Research
Alector (ALEC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Alector (ALEC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Think Alector (ALEC) Could Surge 142.53%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 142.5% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Alector (ALEC) Loses -38.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Alector (ALEC) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study
by Zacks Equity Research
Alector (ALEC) completes enrolment in a mid-stage study evaluating its investigational monoclonal antibody in patients with early Alzheimer's disease. Data from the study is expected before year-end.
UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why
by Zacks Equity Research
This jump in UroGen's (URGN) stock price is attributable to positive data from two late-stage studies on bladder cancer therapy. An FDA filing for the candidate is expected next year.
Wall Street Analysts Believe Alector (ALEC) Could Rally 102%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 102% in Alector (ALEC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Alector (ALEC) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 102.47% and 1,450.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Does Alector (ALEC) Have the Potential to Rally 86.38% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at an 86.4% upside potential for Alector (ALEC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Alector (ALEC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of 26.67% and 79.32%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Alector (ALEC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Options Traders Betting on a Big Move in Alector (ALEC) Stock?
by Zacks Equity Research
Investors need to pay close attention to Alector (ALEC) stock based on the movements in the options market lately.
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alector (ALEC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Alector (ALEC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Lower Patient Days Hurt Community Health (CYH) Q4 Earnings?
by Zacks Equity Research
Community Health's (CYH) fourth-quarter results are likely to reflect growth in adjusted admissions and operating expenses.
Alector (ALEC) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Alector (ALEC) delivered earnings and revenue surprises of -30.23% and 71.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avidity Biosciences, Inc. (RNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 15.46% and 3.85%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?